Acetylation Suppresses the Proapoptotic Activity of GD3 Ganglioside by Malisan, Florence et al.
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2002/12/1535/7 $5.00
Volume 196, Number 12, December 16, 2002 1535–1541
http://www.jem.org/cgi/doi/10.1084/jem.20020960
 
1535
 
Acetylation Suppresses the Proapoptotic Activity of
GD3 Ganglioside
 
Florence Malisan,
 
1
 
 Luigi Franchi,
 
1
 
 Barbara Tomassini,
 
1
 
 Natascia Ventura,
 
1
 
Ivano Condò,
 
1 
 
Maria Rita Rippo,
 
1
 
 Alessandra Ruﬁni,
 
1
 
 Laura Liberati,
 
1
 
Claudia Nachtigall,
 
2
 
 Bernhard Kniep,
 
2
 
 and Roberto Testi
 
1
 
1
 
Laboratory of Immunology and Signal Transduction, Department of Experimental Medicine and Biochemical 
Sciences, University of Rome Tor Vergata, 00133 Rome, Italy
 
2
 
Institute of Immunology, Technical University of Dresden, 01307 Dresden, Germany
 
Abstract
 
GD3 synthase is rapidly activated in different cell types after specific apoptotic stimuli. De novo
synthesized GD3 accumulates and contributes to the apoptotic program by relocating to mito-
chondrial membranes and inducing the release of apoptogenic factors. We found that sialic acid
acetylation suppresses the proapoptotic activity of GD3. In fact, unlike GD3, 9-O-acetyl-GD3
is completely ineffective in inducing cytochrome c release and caspase-9 activation on isolated
mitochondria and fails to induce the collapse of mitochondrial transmembrane potential and
cellular apoptosis. Moreover, cells which are resistant to the overexpression of the GD3 syn-
thase, actively convert de novo synthesized GD3 to 9-O-acetyl-GD3. The coexpression of
GD3 synthase with a viral 9-O-acetyl esterase, which prevents 9-O-acetyl-GD3 accumulation,
reconstitutes GD3 responsiveness and apoptosis. Finally, the expression of the 9-O-acetyl es-
terase is sufficient to induce apoptosis of glioblastomas which express high levels of 9-O-acetyl-
GD3. Thus, sialic acid acetylation critically controls the proapoptotic activity of GD3.
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Introduction
 
Lipid and glycolipid diffusible mediators are important
components of the apoptotic program in many cell types.
GD3 ganglioside is actively synthesized and transiently accu-
mulates intracellularly within 30 min from the clustering of
death receptors in hemopoietic cells undergoing apoptosis
(1). De novo synthesis of GD3 induced by engagement of
death receptors requires the previous accumulation of cer-
amide deriving from the hydrolysis of membrane sphingo-
myelin, by the action of acidic sphingomyelinase (2). The
 
final step of de novo GD3 synthesis is catalyzed by the
 
 
 
-2,8-sialyltransferase (GD3 synthase or ST8Sia-I), an
early Golgi-resident luminal enzyme which mediates the
attachment of a second sialic acid to the sialic acid of GM3
ganglioside, its main substrate. Transient accumulation of
GD3 in the early Golgi is followed by relocation of GD3 to
mitochondrial membranes (3). GD3 directly affects mito-
chondrial physiology by inducing the opening of the per-
 
meability transition pore complex (PTPC),
 
*
 
 the collapse of
mitochondrial transmembrane potential, mitochondrial
swelling, uncoupling of the respiratory chain, generation of
reactive oxygen species (ROS), and the release of apopto-
genic factors such as cytochrome c and apoptosis-inducing
factor (AIF; references 3–6). GD3-induced mitochondrial
changes result in the activation of caspase-9 and are syner-
gized by bax and antagonized by bcl-2 (3, 7). Mitochon-
drial changes and apoptosis can be induced directly by ex-
posing the cells to natural or synthetic GD3 (8), or by
forcing the expression of the GD3 synthase (1). Accord-
ingly, blocking the expression of the GD3 synthase signifi-
 
cantly prevents death receptor–induced and ceramide-
induced apoptosis.
In some cell types, GD3 ganglioside is therefore a pow-
erful inducer of mitochondrial dysfunction and apoptosis.
However, the molecular mechanisms which regulate GD3
activity are completely unknown.
GD3 contains two sialic acid residues, sequentially at-
tached to the galactose residue. The most common
postsynthetic modification of GD3 is O-acetylation at the
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C9 position of its terminal sialic acid (9–11). The ester
bond is catalyzed by specific, yet elusive, acetyltransferases
(12), which probably colocalize with the GD3 synthase in
the same Golgi compartments. The resulting 9-O-acetyl
GD3 is expressed in a developmentally regulated and tis-
sue-specific manner (13), and is abundant in a variety of tu-
mors (14–16). Specific O-acetylesterases are responsible for
the hydrolysis of the ester bond (17), converting the 9-O-
acetyl GD3 back to GD3 (18). The ratio between acety-
lated and nonacetylated forms of GD3, and their subcellular
distribution, may vary among different cells (19), suggest-
ing cell-specific regulatory mechanisms and compartmen-
talized functions. O-acetylation affects in fact the structural
properties of sialic acid, changing binding and antigenic
specificities, as well as biological activities (9).
We therefore investigated whether O-acetylation affects
the proapoptotic activity of GD3. We found that 9-O-
acetyl GD3 is completely ineffective in inducing mito-
chondrial changes and cellular apoptosis and that some cells
convert GD3 into 9-O-acetyl GD3 to prevent GD3-
induced apoptosis. By turning proapoptotic GD3 into 9-O-
acetyl GD3, sialic acid acetylation may therefore cooperate
to cell survival.
 
Materials and Methods
 
Cell Culture and Reagents.
 
HEK-293 and U87 cells were cul-
tured in DMEM supplemented with 10% fetal bovine serum.
U118 were cultured in minimum essential medium (MEM) with
Earle’s Salts supplemented with 10% fetal bovine serum. GD3
was purchased from Sigma-Aldrich or Qbiogene. 9-O-acetyl
GD3 was purified from bovine buttermilk as described previously
(20). Monoclonal antibody for cytochrome c was from BD Bio-
sciences (clone 7H8.2C12). Polyclonal antibody against caspase-9
p18 subunit was from Santa Cruz Biotechnology, Inc. (clone
H-170). The anti-GD3 mAb (IgG3) was protein G-purified from
the R24 hybridoma supernatant. Anti-9-O-acetyl GD3 mAb
(IgM) was obtained from the M-T6004 hybridoma supernatant (a
gift from Dr. E. Rieber, University of Dresden, Dresden, Ger-
many; reference 21). The anti-9-O-acetyl GD3 P-Path mAb
(IgM) is a gift of Dr. Y. Hirabayashi (Riken Institute, Saitama, Ja-
pan; reference 22). The anti-9-O-acetyl GD3 mAb UM4D4
(Ancell), was used for FACS
 
®
 
 staining (23).
 
DNA Constructs.
 
GD3 synthase plasmids: WT GD3 synthase
fused to the GFP, pEGFPwtST8, and its inactive mutant
pEGFPmST8 have been described previously (1). The plasmid
GFP-spectrin was a kind gift from Dr. R. Kalejta (Princeton Uni-
versity, Princeton, NJ; reference 24). The plasmid pAIISVL
 
2
 
-
CHA4 containing the viral 9-O-acetylesterase gene was a kind
gift of Dr. P. Palese (Mount Sinai Medical Center, New York,
NY). The cDNA was further cloned into the expression vector
pcDNA3 (Invitrogen). The viral 9-O-acetylesterase dead mutant
S57A was generated using the Quick Change Site-directed Mu-
tagenesis kit (Stratagene) and WT viral 9-O-acetylesterase as a
template. Each mutation was confirmed by sequencing.
 
TLC, Immunostaining, and FACS
 
®
 
 Analysis.
 
Gangliosides
were extracted as previously described with minor modifications
(1). Briefly, cells were disrupted by three cycles of freezing and
thawing. The aqueous pellet was extracted with chloroform/
methanol (1:2, vol/vol) after 30 s sonication at 10 Watts. After 20
min vortex and 5 min centrifugation at 15,000 
 
g
 
, the upper phase
 
was recovered and water was added to obtain a final ratio of chlo-
roform/methanol/water (4:8:5, vol/vol/vol). After vortex and 5
min centrifugation at 15,000 
 
g
 
, the upper phase was recovered.
Two volumes of methanol were added and evaporated to dryness
under nitrogen gas. Gangliosides were then resuspended in chlo-
roform/methanol (2:1, vol/vol) and loaded on a silica gel 60 HP-
TLC plate (Merck) and chromatographed in chloroform/metha-
nol/CaCl
 
2
 
 containing 0.2% (wt/vol; 2:1:0.2, vol/vol/vol). Plates
were treated with 0.5% polyisobutyl-metacrylate in hexane and
dried. To carry out immunostaining for GD3 and 9-O-acetyl
GD3, the plate was first treated with PBS, 0.05% Tween 20, 1%
BSA for 15 min to minimize nonspecific staining, incubated for
1 h with R24 monoclonal anti-GD3-antibody (1:500), or mono-
clonal anti 9-O-acetyl GD3 (P-Path or M-T6004, 1:500 or 1:200
respectively) followed by a horseradish peroxidase–conjugated
anti-IgG or anti-IgM secondary antibody, respectively. Specific
bands were detected by chemiluminescence (ECL; Amersham
Biosciences), according to the manufacturer’s instructions.
Cellular levels of 9-O-acetyl GD3 were also measured by
FACS
 
®
 
 analysis. Briefly, cells were fixed for 15 min at room tem-
perature with 2% paraformaldehyde, permeabilized for 30 min at
37
 
 
 
C with 60 
 
 
 
M digitonine, and treated with 3% FCS at 37
 
 
 
C
for 1 h to minimize nonspecific staining. Samples were then in-
cubated for 60 min at 37
 
 
 
C with anti-9-O-acetyl GD3 mAb
(Ancell), or isotype-matched control mAb, at a final concentra-
tion of 20 
 
 
 
g/ml. Cells were further stained with secondary
RPE-conjugated goat anti–mouse IgM antibody (Oxford Bio-
marketing) for 30 min at room temperature and analyzed with a
FACScan™ flow cytometer (Becton Dickinson).
 
Alkaline Treatment of Gangliosides.
 
0.1 mg of 9-O-acetyl GD3
or GD3 were evaporated to dryness under nitrogen gas and resus-
pended in 1 ml of aqueous 1 N NaOH, sonicated for 5 min in an
ultrasonic bath, and incubated for 60 min at 37
 
 
 
C. After neutral-
ization with 1 ml of 1 N acetic acid, the recovered glycolipids
were purified with C18 column (Supelclean LC-18, Supelco),
run on an HP-TLC plate, and visualized by 
 
 
 
-naphtol/sulfuric
acid staining.
 
Liver Mitochondria Purification and Release of Apoptogenic Fac-
tors.
 
Mitochondria were purified from mouse liver, as described
(3), and resuspended in 300 mM sucrose, 0.2 mM EGTA, 5 mM
TES, pH 7.2. For the induction of permeability transition (PT),
mitochondria (5 mg protein/ml) were resuspended in PT buffer
(200 mM sucrose, 10 mM Tris-MOPS, pH 7.2, 5 mM Tris-suc-
cinate, pH 7.2, 1 mM Tris-phosphate, pH 7.2, 10 
 
 
 
M EGTA-
Tris, 2 
 
 
 
M rotenone, and 5 
 
 
 
M Ca
 
2
 
 
 
) and after addition of 200
 
 
 
M Ca
 
2
 
 
 
, 10–40 
 
 
 
M GD3, or 9-O-acetyl GD3 for 30 min, su-
pernatants from mitochondria were recovered by centrifugation
(15,000 
 
g
 
 for 20 min). Supernatants were then analyzed by SDS-
PAGE, blotted onto nitrocellulose membranes and probed with
specific antibodies. The following antibodies were used: mouse
anti-cytochrome c mAb (1:500 in PBS, 0.1% Tween 20, 5% milk
powder), rabbit anti-caspase-9 polyclonal antibody (1:200 in
PBS, 0.1% Tween 20, 5% milk powder). Horseradish peroxi-
dase–conjugated secondary antibodies were used and Western
blots were revealed by ECL.
 
Transfections and Apoptosis Analysis.
 
HEK-293 cells were trans-
fected with the calcium phosphate method. The day before trans-
fection, 6.5 
 
 
 
 10
 
6
 
 cells were plated in 10-cm dishes. The next
day, 70–80% confluent cells were transfected with 8 
 
 
 
g of the
different expression vectors. 40 h after transfection, cells were
harvested for TLC analysis. 10-cm dishes were divided in two
equal parts, one for GD3 analysis, the other one for 9-O-acetyl
GD3. U87 and U118 cells were transfected with Lipofectamine 
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2000 according to manufacturer’s instructions. Briefly, cells were
cotransfected with pEGFP vector (CLONTECH Laboratories,
Inc.) or GFP-spectrin and vector of interest in a 1:3 ratio. Mito-
chondrial damage was assessed using JC-1 (Molecular Probes) to
analyze the loss of mitochondrial transmembrane potential
(
 
  
 
m) and nuclear condensation/fragmentation was evaluated
using Hoechst 33342 (Molecular Probes). Carbocyanine dye JC-1
exists as a monomer or as J-aggregate forms, depending on con-
centration and membrane potential. While polarized mitochon-
dria exhibit J-aggregates, with an emission max of 590 nm, depo-
larized mitochondria exhibit monomers, with an emission max at
527 nm, thus permitting to discriminate the mitochondrial trans-
membrane potential with a fluorescence microscope by using a
standard fluorescein longpass optical filter (25). Briefly, HEK-293
cells were stained 30 min with JC-1 (1 
 
 
 
g/ml) and Hoechst (500
ng/ml) and then analyzed with a fluorescence microscope (IX50;
Olympus) with adequate filters. Typically, two independent in-
vestigators scored the apoptotic cells in blind, counting at least
200 cells from nine different microscopic fields.
To score the percentage of transfected (green) HEK-293 cells
undergoing apoptosis, cells were harvested 16 h after transfection
and replated onto coverslips. Cells were then stained with
Hoechst 33342 (500 ng/ml for 30 min) and cell death was calcu-
lated counting the condensed and/or fragmented nuclei, as de-
tailed above. For U87 and U118, cells were stained with Hoechst
(500 ng/ml for 30 min) 24 h after transfection and cell death was
calculated counting the condensed and/or fragmented nuclei of
transfected (green) cells, as described above.
 
Results and Discussion
 
9-O-acetyl GD3 Is Unable to Induce Cytochrome c Release
from Mitochondria and Activation of Caspase-9.
 
The interac-
tion of GD3 with mitochondrial membranes causes cyto-
chrome c release and caspase-9 activation, thereby trigger-
ing apoptosis (3–5). To verify whether 9-O-acetyl GD3
retains the proapoptotic functions of GD3, purified mito-
chondria were exposed to 9-O-acetyl GD3 and the
amount of cytochrome c released in the supernatants quan-
titated by Western blot analysis and immunostaining. Fig. 1
B shows that, unlike GD3, purified 9-O-acetyl GD3 is
completely unable to induce the release of cytochrome c
from mitochondria. Accordingly, exposure of isolated mi-
tochondria to purified 9-O-acetyl GD3 did not result in
caspase-9 activation, unlike GD3, as revealed by the detec-
tion of the caspase-9 p35 fragment in the supernatants, by
Western blot analysis and immunostaining (Fig. 1 C). To
verify that the acetyl moiety is responsible for the loss of
function of 9-O-acetyl GD3, we deacetylated 9-O-acetyl
GD3 in vitro by alkaline treatment, in order to recover
GD3 (Fig. 1 A). Deacetylated 9-O-acetyl GD3 is able to
induce cytochrome c release from isolated mitochondria to
the same extent as GD3 (Fig. 1 B).
We also investigated whether 9-O-acetyl GD3 could
inhibit GD3-induced mitochondrial changes. GD3 and
9-O-acetyl GD3 were mixed in different ratios within a
fixed total amount of gangliosides (40 
 
 
 
M) which did not
cause non specific, detergent-like effects. Isolated mito-
chondria were exposed to the different ganglioside mixes
and the release of cytochrome c quantitated by Western
blot analysis and immunostaining. Fig. 1 D shows that cy-
tochrome c was similarly released by mitochondria ex-
posed to the GD3/9-O-acetyl GD3 mixes or to GD3
alone, indicating that 9-O-acetyl GD3 does not inhibit
GD3-induced changes.
 
9-O-acetyl GD3 Is Unable to Trigger Mitochondrial Changes
and Apoptosis.
 
Exposure of intact cells to exogenous GD3
induces the collapse of mitochondrial transmembrane po-
tential (
 
  
 
m) and triggers apoptosis. To investigate
whether sialic acid acetylation affected the proapoptotic ac-
tivity of GD3, HEK-293 cells were exposed to 9-O-acetyl
GD3. As shown in Fig. 2, 9-O-acetyl GD3 could not affect
the mitochondrial transmembrane potential of HEK-293
cells (Fig. 2 A), nor induce apoptosis (Fig. 2 B). In vitro
deacetylation of sialic acid restored the ability of 9-O-acetyl
GD3 to induce mitochondrial changes and apoptosis.
Figure 1. 9-O-acetyl GD3 is unable to induce mitochondrial damage.
(A) GD3 and 9-O-acetyl GD3 (acGD3) were subjected to alkaline treat-
ment, and run on TLC for 50 min, along with untreated GD3 and 9-O-
acetyl GD3. (B) Isolated mitochondria were treated for 40 min with 200
 M Ca2 , 30  M GD3, 30  M 9-O-acetyl GD3 (acGD3), 30  M de-
acetylated 9-O-acetyl GD3 (de-acGD3), then supernatants subjected to
Western blotting with anti-cytC mAb. (C) Isolated mitochondria were
treated for 30 min with the indicated concentrations of GD3 and 9-O-
acetyl GD3, then supernatants subjected to Western blotting with anti-
caspase-9 p35 mAb. Data are representative of three independent experi-
ments. (D) Isolated mitochondria were treated for 40 min with the indicated
concentrations of GD3/9-O-acetyl GD3 mixes or GD3 alone, then su-
pernatants subjected to Western blotting with anti-cytC mAb. Data are
representative of two independent experiments. 
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Moreover, competition experiments indicated that 9-O-
acetyl GD3 could not prevent GD3-induced apoptosis (un-
published data). Together these results strongly suggested
that sialic acid 9-O-acetylation might represent a mecha-
nism to inactivate GD3 in vivo. We therefore further in-
vestigated the functional implications of this finding.
 
Cells Which Are Resistant to Endogenous GD3 Accumulation
Synthesize 9-O-acetyl GD3.
 
Several cell lines undergo
massive mitochondrial damage and apoptosis upon acute
intracellular GD3 accumulation, a condition which can be
experimentally achieved by GD3 synthase overexpression.
Selected cell lines, however, while still sensitive to exoge-
nous GD3 exposure, fail to undergo apoptosis upon GD3
synthase overexpression and endogenous GD3 accumula-
tion. As shown in Fig. 3 A, HEK-293 cells, which undergo
apoptosis upon exposure to exogenous GD3 (Fig. 2 B), are
completely resistant to GD3 synthase overexpression. To
verify that GD3 synthase overexpression was indeed induc-
ing GD3 accumulation in HEK-293 cells, the amount of
GD3 was assessed by TLC and immunostaining. Fig. 3 B
shows that HEK-293 cells transfected with GD3 synthase,
but not with a catalytically dead GD3 synthase mutant
which lacks part of the catalytic site (1), accumulate GD3
efficiently. Interestingly, a simultaneous immunostaining
for 9-O-acetyl GD3 revealed that GD3 synthase-trans-
fected HEK-293 were also accumulating 9-O-acetyl GD3,
indicating that part of the de novo synthesized GD3 was
converted to 9-O-acetyl GD3, by the concomitant activa-
tion of endogenous sialic acid acetyltransferases.
 
In Vivo Deacetylation of De Novo–synthesized 9-O-acetyl
GD3 Triggers Apoptosis.
 
The above mentioned findings
suggested that GD3 to 9-O-acetyl GD3 conversion, medi-
ated by endogenous sialic acid acetyltransferases, might rep-
resent an efficient cell survival strategy in response to stress-
induced acute GD3 accumulation. To test this hypothesis,
we first decided to force the in vivo deacetylation of de
novo–synthesized 9-O-acetyl GD3 by coexpressing a spe-
cific sialic acid acetylesterase. We used the influenza type C
viral 9-O-acetylesterase, known to efficiently de-acetylate
9-O-acetyl GD3 in mammalian cells (26). We also pre-
pared an enzymatically dead version of the same viral acet-
ylesterase by substituting a critical Ser57 residue with Ala,
based on structural informations (27). We transiently coex-
pressed the wild-type 9-O-acetylesterase, or the dead 9-O-
acetylesterase, together with the wild-type GD3 synthase,
or the dead GD3 synthase in HEK-293 cells. The accumu-
lation of GD3 and 9-O-acetyl GD3 in cotransfected cell
cultures was monitored along with the induction of apop-
tosis. As shown in Fig. 4 A, the coexpression of both dead
mutants, or the coexpression of the dead GD3 synthase to-
gether with the wild-type 9-O-acetylesterase, did not result
in any GD3 or 9-O-acetyl GD3 accumulation. Moreover,
the coexpression of the wild-type GD3 synthase together
with the dead 9-O-acetylesterase, resulted in the accumula-
tion of both GD3 and 9-O-acetyl GD3. This last condition
parallels what already shown in Fig. 3, and no specific
apoptosis can be induced in HEK-293 cells (Fig. 4 B).
However, the coexpression of the wild-type forms of both
enzymes resulted in enhanced accumulation of GD3 and in
Figure 2. 9-O-acetyl GD3 is unable to induce mitochondrial damage
and apoptosis of HEK-293 cells. The percentage of HEK-293 cells with
  m loss (A) or condensed nuclei (B) was analyzed at 30 h after stimula-
tion with 200  M of exogenous GD3, 9-O-acetyl GD3 (acGD3), and
deacetylated 9-O-acetyl GD3 (de-ac-GD3). Data represent the mean   1
SD from three independent experiments. Figure 3. HEK-293 cells are resistant to endogenous GD3 accumula-
tion and synthesize 9-O-acetyl GD3. (A) The percentage of apoptotic
HEK-293 nuclei was analyzed 40 h after transfection with empty vector
(vector), wild-type GD3 synthase (wST8), dead mutant GD3 synthase
(mST8), and caspase-8 as a positive control. Data represent the mean   1
SD from five independent experiments. (B) GD3 and 9-O-acetyl GD3
content of HEK-293 cells was analyzed by TLC and immunostaining 40 h
after transfection with the indicated constructs. Data are representative of
six independent experiments. 
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the disappearance of 9-O-acetyl GD3, due to the action of
the 9-O-acetylesterase. Importantly, in this last condition,
extensive apoptosis of HEK-293 could be induced (Fig. 4
B). Apoptosis is strictly dependent on specific deacetylation
of 9-O-acetyl GD3, since the dead 9-O-acetylesterase is
ineffective, and it does not occur in the absence of de novo
9-O-acetyl GD3 synthesis. These results strongly suggest
that when the attempt to transform part of the accumulat-
ing GD3 into 9-O-acetyl GD3 is reversed by the action of
the 9-O-acetylesterase, a critical GD3 threshold is ex-
ceeded and HEK-293 cells undergo apoptosis.
 
Deacetylation of Endogenous 9-O-acetyl GD3 Directly Induces
Apoptosis of Human Tumor Cells.
 
To further support the
notion that the ratio between GD3 and 9-O-acetyl GD3
might critically affect survival of tumor cells, we investi-
gated tumor cell lines which constitutively synthesize and
express both GD3 and 9-O-acetyl GD3. We tested the hy-
pothesis that, by selectively breaking the endogenous
GD3/9-O-acetyl GD3 balance in favor of GD3, we would
induce apoptosis. The viral 9-O-acetylesterase is known to
deacetylate 9-O-acetyl GD3 in neural tumor cells (18).
Therefore, the viral 9-O-acetylesterase, and its catalytically
dead mutant, were expressed in the human glioblastoma
cells U118, which constitutively express both GD3 and
9-O-acetyl GD3, as assessed by TLC and immunostaining
(Fig. 5 A). The 9-O-acetylesterase was also expressed in the
human glioblastoma U87, which expresses GD3 but lacks
detectable 9-O-acetyl GD3 (Fig. 5 A). As shown in Fig. 5
 
B, the 9-O-acetylesterase, but not its catalytically dead mu-
tant, directly triggered apoptosis of U118 cells expressing
9-O-acetyl GD3. By contrast, the 9-O-acetylesterase, as
well as its catalytically dead mutant, did not induce apopto-
sis in U87 cells lacking 9-O-acetyl GD3 (Fig. 5 C). To ver-
ify that the viral 9-O-acetylesterase was in fact active in
glioblastoma cells, U118 cells were cotransfected with
9-O-acetylesterase and GFP-spectrin to allow the detection
and electronic gating of transfected cells by FACS
 
®
 
 analysis
(24). Fig. 5 D shows that the levels of cellular 9-O-acetyl
GD3 were significantly decreased in U118 cells transfected
with the 9-O-acetylesterase, compared with vector-trans-
Figure 4. Deacetylation of de novo synthesized 9-O-acetyl GD3 triggers
apoptosis of HEK-293 cells. (A) GD3 and 9-O-acetyl GD3 content of
HEK-293 cells was analyzed by TLC and immunostaining 40 h after
transfection with wild-type GD3 synthase (ST8), wild-type 9-O-acetyl-
esterase (Est), dead mutant GD3 synthase (mST8), and dead mutant 9-O-
acetylesterase (mEst). Data are representative of three independent exper-
iments. (B) The percentage of apoptotic HEK-293 nuclei was analyzed
40 h after transfection with the indicated constructs. Data represent the
mean   1 SD from three independent experiments.
Figure 5. Deacetylation of endogenous 9-O-acetyl GD3 induces
apoptosis of U118 glioblastoma cells. (A) The expression of GD3 and
9-O-acetyl GD3 from U118 and U87 glioblastoma cells was analyzed by
TLC-immunostaining. The percentage of apoptotic U118 (B) and U87
(C) cells was analyzed 24 h after transfection with empty vector (vector),
dead mutant 9-O-acetylesterase (mEst), wild-type 9-O-acetylesterase
(Est), and caspase-8 as a positive control. The data represent the mean  
1 SD from five independent experiments. (D) 24 h after cotransfection
with GFP-spectrin and empty vector (vector), or 9-O-acetylesterase (Est),
U118 glioma cells were stained with anti-9-O acetyl GD3 mAb (open ar-
eas) or control antibody (shaded areas), and secondary RPE-conjugated
antibody. The expression of 9-O-acetyl GD3 within electronically gated
transfected cells was analyzed by flow cytometry. Data are representative
of three independent experiments. 
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fected cells. Together these results indicated that the 9-O-
acetylesterase was specifically acting upon endogenous
9-O-acetyl GD3 and that the GD3/9-O-acetyl GD3 ratio
may significantly control survival of tumor cells.
 
Concluding Remarks.
 
Mitochondria act as “sensors” of
stress-induced lipid and glycolipids, from simple unicellular
organisms to metazoans (28–30). The stress mediator cer-
amide, generated by the action of sphingomyelinases, is
largely converted to GD3 ganglioside. In different cell
types, upon acute GD3 accumulation and relocalization to
mitochondrial membranes, the mitochondrial PTPC opens
and, concomitantly, cytochrome c is released, causing the
activation of caspase-9 and downstream caspases (3–5).
Some tumor cells, however, may actively O-acetylate the
terminal sialic acid of GD3, generating 9-O-acetyl GD3,
thus enhancing their in vivo metastatic potential. In fact,
C6 rat glioma cells transfected with the GD3 synthase ex-
press both GD3 and 9-O-acetyl GD3 and show increased
tumorigenicity and invasiveness (31). We found that 9-O-
acetyl GD3 is completely unable to induce mitochondrial
changes and cellular apoptosis. Sialic acid O-acetylation is
likely to critically modify either hydrophobicity or steric
conformation of GD3, so that putative interactions with
PTPC elements or other components of the mitochondrial
membrane are prohibited. By turning part of proapoptotic
GD3 into the “harmless” 9-O-acetyl GD3, sialic acid
O-acetylation acts as an effective antiapoptotic mechanism.
Sialic acid O-acetylation may therefore represent an impor-
tant strategy adopted by tumor cells to escape acute GD3
accumulation during cellular stress and to enhance survival.
Acetylation is a covalent modification of biological mol-
ecules, which may profoundly affect their stability, speci-
ficity, and function (32, 33). Specific acetyltransferases and
deacetylases are therefore involved in multiple biological
processes, including apoptosis. It has been shown, in fact,
that N-acetylation of critical lysines in the COOH termi-
nus of tumor suppressor p53, controlled by histone acetyl-
transferases and specific deacetylases (34), modulates p53
function, contributing to the regulation of the apoptotic
program (35). Similarly, N-acetylation may regulate the
proapoptotic activity of p73 and Rb proteins (36, 37).
Here we show that sialic acid O-acetylation of GD3
ganglioside controls its ability to induce mitochondrial
changes and to trigger apoptosis, providing the first exam-
ple of gain/loss of proapoptotic function regulated by
acetylation in a lipid mediator. Importantly, the ratio be-
tween GD3 and 9-O-acetyl GD3 may critically affect sur-
vival of tumor cells, as shown here in glioblastoma cells.
Little molecular information is available at the moment on
human GD3 acetyltransferases and acetylesterases. Further
characterization of the enzymes involved in the control of
GD3 acetylation in humans are expected to provide inter-
esting new targets for the pharmacological manipulation of
the apoptotic program.
 
We thank Dr. E. Rieber, (University of Dresden, Germany), Dr.
Y. Hirabayashi (Riken Institute, Japan), Dr. P. Palese, (Mount Sinai
Medical Center, New York), and Dr. R. Kalejta (Princeton Uni-
 
versity, NJ) for reagents.
This work has been supported by the Associazione Italiana
Ricerca sul Cancro, the Agenzia Spaziale Italiana, the Ministero Is-
truzione Universita’ e Ricerca, the European Commission, and by
a grant from the Deutsche Forschungsgemeinschaft (Kn 442/1-3).
I. Condò is a recipient of a Fondazione Italiana Ricerca sul Cancro
fellowship. M.R. Rippo is currently at the Institute of Experimen-
tal Pathology, University of Ancona, Italy.
 
Submitted: 12 June 2002
Revised: 25 September 2002
Accepted: 15 October 2002
 
References
 
1. De Maria, R., M.L. Lenti, F. Malisan, F. d’Agostino, B. To-
massini, A. Zeuner, M.R. Rippo, and R. Testi. 1997. Re-
quirement for GD3 ganglioside in CD95- and ceramide-
induced apoptosis. 
 
Science.
 
 277:1652–1655.
2. De Maria, R., M.R. Rippo, H.E. Schuchman, and R. Testi.
1998. Acidic sphingomyelinase (ASM) is necessary for Fas-
induced GD3 ganglioside accumulation and efficient apopto-
sis of lymphoid cells. 
 
J. Exp. Med.
 
 187:897–902.
3. Rippo, M.R., F. Malisan, L. Ravagnan, B. Tomassini, I.
Condò, P. Costantini, S.A. Susin, A. Rufini, M. Todaro, G.
Kroemer, and R. Testi. 2000. GD3 ganglioside directly tar-
gets mitochondria in a bcl-2-controlled fashion. 
 
FASEB J.
 
14:2047-2054.
4. Scorrano, L., V. Petronilli, F. Di Lisa, and P. Bernardi. 1999.
Commitment to apoptosis by GD3 ganglioside depends on
opening of the mitochondrial permeability transition pore. 
 
J.
Biol. Chem.
 
 274:22581–22585.
5. Kristal, B.S., and A.M. Brown. 1999. Apoptogenic ganglio-
side GD3 directly induces the mitochondrial permeability
transition. 
 
J. Biol. Chem.
 
 274:23169–23175.
6. Garcia-Ruiz, C., A. Colell, R. Paris, and J.C. Fernandez-
Checa. 2000. Direct interaction of GD3 ganglioside with mi-
tochondria generates reactive oxygen species followed by mi-
tochondrial permeability transition, cytochrome c release,
and caspase activation. 
 
FASEB J.
 
 14:847–858.
7. Pastorino, J.G., M. Tafani, R.J. Rothman, A. Marcinevi-
ciute, J.B. Hoek, and J.L. Farber. 1999. Functional conse-
quences of the sustained or transient activation by bax of the
mitochondrial permeability transition pore. 
 
J. Biol. Chem.
 
274:31734–31739.
8. Castro-Palomino, J.C., B. Simon, O. Speer, M. Leist, and
R.R. Schmidt. 2001. Synthesis of ganglioside GD3 and its
comparison with bovine GD3 with regard to oligodendro-
cyte apoptosis mitochondrial damage. 
 
Chemistry.
 
 7:2178–
2184.
9. Varki, A. 1997. Sialic acids as ligands in recognition phenom-
ena. 
 
FASEB J.
 
 11:248–255.
10. Klein, A., and P. Roussel. 1998. O-Acetylation of sialic acids.
 
Biochimie.
 
 80:49–57.
11. Schauer, R. 2000. Achievements and challenges of sialic acid
research. 
 
Glycoconj. J.
 
 17:485–499.
12. Shen, Y., J. Tiralongo, M. Iwersen, B. Sipos, H. Kalthoff,
and R. Schauer. 2002. Characterization of the sialate-7(9)-
O-acetyltransferase from the microsomes of human colonic
mucosa. 
 
Biol. Chem. 
 
383:307–317.
13. Varki, A. 1992. Diversity in the sialic acids. 
 
Glycobiology.
 
2:25–40.
14. Cheresh, D.A., R.A. Reisfeld, and A.P. Varki. 1984. 
1541
 
Malisan et al.
 
O-acetylation of disialoganglioside GD3 by human mela-
noma cells creates a unique antigenic determinant. 
 
Science.
 
225:844–846.
15. Fuentes, R., R. Allman, and M.D. Mason. 1997. Ganglioside
expression in lung cancer cell lines. 
 
Lung Cancer.
 
 18:21–33.
16. Fahr, C., and R. Schauer. 2001. Detection of sialic acids and
gangliosides with special reference to 9-O-acetylated species
in basaliomas and normal human skin. 
 
J. Invest. Dermatol.
 
116:254–260.
17. Takematsu, H., S. Diaz, A. Stoddart, Y. Zhang, and A.
Varki. 1999. Lysosomal and cytosolic sialic acid 9-O-acetyl-
esterase activities can be encoded by one gene via differential
usage of a signal peptide-encoding exon at the N terminus. 
 
J.
Biol. Chem.
 
 274:25623–25631.
18. Ariga, T., G.M. Blaine, H. Yoshino, G. Dawson, T. Kanda,
G.C. Zeng, T. Kasama, Y. Kushi, and R.K. Yu. 1995. Gly-
cosphingolipid composition of murine neuroblastoma cells:
O-acetylesterase gene downregulates the expression of
O-acetylated GD3. 
 
Biochemistry. 
 
34:11500–11507.
19. Gocht, A., A. Gadatsch, G. Rutter, and B. Kniep. 2000.
CDw60: an antigen expressed in many normal tissues and in
some tumours. 
 
Histochem. J.
 
 32:447–456.
20. Kniep, B., C. Claus, J. Peter-Katalinic, D.A. Monner, W.
Dippold, and M. Nimtz. 1995. 7-O-acetyl-GD3 in human
T-lymphocytes is detected by a specific T-cell-activating
monoclonal antibody. 
 
J. Biol. Chem.
 
 270:30173–30180.
21. Claus, C., A. Gocht, R. Schwartz-Albiez, H. Lünsdorf, and
B. Kniep. 2002. CD60: Specificity of the antibodies, distribu-
tion of the antigens, and the functional aspects. 
 
In
 
 Leucocyte
Typing VII. D. Mason, P. André, A. Bensussan, C. Buckley,
C. Civin, E. Clark, M. de Haas, S. Goyert, M. Hadam, D.
Hart, et al., editors.
 
 
 
Oxford University Press, Oxford, UK.
187–188.
22. Leclerc, N., G.A. Schwarting, K. Herrup, R. Hawkes, and
M. Yamamoto. 1992. Compartmentation in mammalian cer-
ebellum: Zebrin II and P-path antibodies define three classes
of sagittally organized bands of Purkinje cells. 
 
Proc. Natl.
Acad. Sci. USA. 
 
89:5006–5010.
23. Kniep, B., J. Peter-Katalinic, W. Flegel, H. Northoff, and
E.P. Rieber. 1992. CDw 60 antibodies bind to acetylated
forms of ganglioside GD3. 
 
Biochem. Biophys. Res. Commun.
 
187:1343–1349.
24. Kalejta, R.F., T. Shenk, and A.J. Beavis. 1997. Use of a
membrane-localized green fluorescent protein allows simul-
taneous identification of transfected cells and cell cycle analy-
sis by flow cytometry. 
 
Cytometry. 
 
29:286–291.
25. Reers, M., T.W. Smith, and L.B. Chen. 1991. J-aggregate
formation of a carbocyanine as a quantitative fluorescent indi-
cator of membrane potential. 
 
Biochemistry. 
 
30:4480–4486.
26. Varki, A., F. Hooshmand, S. Diaz, N.M. Varki, and S.M.
Hedrick. 1991. Developmental abnormalities in transgenic
mice expressing a sialic acid-specific 9-O-acetylesterase. 
 
Cell.
 
65:65–74.
27. Rosenthal, P.B., X. Zhang, F. Formanowski, W. Fitz, C.H.
Wong, H. Meier-Ewert, J.J. Skehel, and D.C. Wiley. 1998.
Structure of the haemagglutinin-esterase-fusion glycoprotein
of influenza C virus. Nature. 396:92–96.
28. Kolesnick, R.N., F.M. Goni, and A. Alonso. 2000. Com-
partmentalization of ceramide signaling: physical foundations
and biological effects. J. Cell Physiol. 184:285–300.
29. Hannun, Y. 2000. Ceramide in the eukaryotic stress re-
sponse. Trends Cell Biol. 10:73–80.
30. Tomassini, B., and R. Testi. 2002. Mitochondria as sensors of
sphingolipids. Biochimie. 84:123–129.
31. Sottocornola, E., I. Colombo, V. Vergani, G. Taraboletti,
and B. Berra. 1999. Increased tumorigenicity and invasive-
ness of C6 rat glioma cells transfected with the human alpha-
2,8 sialyltransferase cDNA. Invasion Metastasis. 18:142–154.
32. Kouzarides, T. 2000. Acetylation: a regulatory modification
to rival phosphorylation? EMBO J. 19:1176–1179.
33. Baker, R.R. 2000. Lipid acetylation reactions and the metab-
olism of platelet-activating factor. Neurochem. Res. 25:677–
683.
34. Vaziri, H., S.K. Dessain, E. Ng-Eaton, S.I. Imai, R.A. Frye,
T.K. Pandita, L. Guarente, and R.A. Weinberg. 2001.
hSIR2(SIRT1) functions as an NAD-dependent p53 de-
acetylase. Cell. 107:149–159.
35. Luo, J., F. Su, D. Chen, A. Shiloh, and W. Gu. 2000.
Deacetylation of p53 modulates its effect on cell growth and
apoptosis. Nature. 408:377–381.
36. Costanzo, A., P. Merlo, N. Pediconi, M. Fulco, V. Sartorelli,
P.A. Cole, G. Fontemaggi, M. Fanciulli, L. Schiltz, G. Blan-
dino, et al. 2001. DNA damage-dependent acetylation of p73
dictates the selective activation of apoptotic target genes. Mol.
Cell. 9:175–186.
37. Chan, H.M., M. Krstic-Demonacos, L. Smith, C. Demona-
cos, and N.B. La Thangue. 2001. Acetylation control of the
retinoblastoma tumour-suppressor protein. Nat. Cell Biol. 3:
667–674.